Company intelligence / Profile preview

AFYIA Diagnostics

Grabels, Occitanie, Franceafyia-diagnostics.com ↗

Ownership: Private
Employees: ~13
Development stage: Commercial

Overview

AFYIA Diagnostics develops and commercializes easy-to-use multiplex diagnostic solutions for human syndromic infectious diseases. Their products leverage artificial intelligence and molecular biology to deliver high reliability at accessible prices. The company operates an R&D laboratory in Grabels, France. No clinical trial results are referenced; the focus is on product development and commercialization.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostics (Biologic)Artificial intelligence-based diagnostics (Device)
Industry: Molecular Diagnostics

Drug pipeline

4 assets

Monkeypox Virus PCR Kit

Commercial

Indications: Monkeypox

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on AFYIA Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFYIA Diagnostics.

Explore the full profile